Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1935 1
1936 3
1937 1
1945 1
1946 9
1947 11
1948 6
1949 10
1950 9
1951 21
1952 32
1953 31
1954 28
1955 27
1956 26
1957 26
1958 21
1959 23
1960 20
1961 20
1962 23
1963 17
1964 35
1965 46
1966 65
1967 68
1968 78
1969 83
1970 101
1971 131
1972 87
1973 105
1974 80
1975 103
1976 117
1977 113
1978 125
1979 118
1980 105
1981 166
1982 123
1983 137
1984 132
1985 125
1986 153
1987 152
1988 142
1989 126
1990 166
1991 145
1992 155
1993 185
1994 149
1995 146
1996 158
1997 161
1998 197
1999 191
2000 203
2001 186
2002 183
2003 200
2004 196
2005 214
2006 223
2007 255
2008 299
2009 259
2010 275
2011 274
2012 288
2013 332
2014 311
2015 290
2016 327
2017 388
2018 377
2019 413
2020 521
2021 552
2022 574
2023 567
2024 223

Text availability

Article attribute

Article type

Publication date

Search Results

11,973 results

Results by year

Filters applied: . Clear all
Page 1
Developing treatment guidelines for myasthenia gravis.
Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance. Sanders DB, et al. Ann N Y Acad Sci. 2018 Jan;1412(1):95-101. doi: 10.1111/nyas.13537. Ann N Y Acad Sci. 2018. PMID: 29381223 Review.
A task force of the Myasthenia Gravis Foundation of America recently published a formal consensus statement intended to be a treatment guide for clinicians caring for myasthenia gravis (MG) patients worldwide. ...The guidance statement is a livi …
A task force of the Myasthenia Gravis Foundation of America recently published a formal consensus statement intended to be a …
[Treatment of juvenile myasthenia gravis].
Arroyo HA. Arroyo HA. Medicina (B Aires). 2019;79 Suppl 3:71-76. Medicina (B Aires). 2019. PMID: 31603848 Free article. Spanish.
Juvenile myasthenia gravis is a rare autoimmune disease, which has made it difficult to collect data from prospective randomized controlled trials to evaluate the efficacy and results of different treatments. Although there are differences between the juvenil …
Juvenile myasthenia gravis is a rare autoimmune disease, which has made it difficult to collect data from prospective randomiz …
Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids.
Tannemaat MR, Verschuuren JJGM. Tannemaat MR, et al. Neuromuscul Disord. 2020 Feb;30(2):111-119. doi: 10.1016/j.nmd.2019.12.003. Epub 2019 Dec 14. Neuromuscul Disord. 2020. PMID: 32007304 Free article. Review.
Myasthenia gravis is an autoimmune disease characterized by dysfunction of the neuromuscular junction. ...Future trials should: select patients with weakness and fatigability that is completely explained by their myasthenia gravis, use a design that av …
Myasthenia gravis is an autoimmune disease characterized by dysfunction of the neuromuscular junction. ...Future trials should …
Myasthenia gravis: subgroup classification and therapeutic strategies.
Gilhus NE, Verschuuren JJ. Gilhus NE, et al. Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3. Lancet Neurol. 2015. PMID: 26376969 Review.
Patients with myasthenia gravis should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroups based on serum antibodies and clinical features include early-onset, late-onset, thymoma, MUSK, LRP4, antibody-negative, and ocular forms …
Patients with myasthenia gravis should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroup …
Myasthenia gravis: an update for the clinician.
Sieb JP. Sieb JP. Clin Exp Immunol. 2014 Mar;175(3):408-18. doi: 10.1111/cei.12217. Clin Exp Immunol. 2014. PMID: 24117026 Free PMC article. Review.
This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays the term 'myasthenia gravis' includes heterogeneous autoimmune diseases, with a postsynaptic defect of neuromuscular tra …
This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Now …
Myasthenia Gravis.
Gilhus NE. Gilhus NE. N Engl J Med. 2016 Dec 29;375(26):2570-2581. doi: 10.1056/NEJMra1602678. N Engl J Med. 2016. PMID: 28029925 Review. No abstract available.
Treatment of Ocular Myasthenia Gravis.
Cornblath WT. Cornblath WT. Asia Pac J Ophthalmol (Phila). 2018 Jul-Aug;7(4):257-259. doi: 10.22608/APO.2018301. Epub 2018 Jul 25. Asia Pac J Ophthalmol (Phila). 2018. PMID: 30044061 Free article. Review.
Unfortunately, there is limited data on the use of individual treatments in ocular myasthenia gravis and no data comparing treatments. Using a combination of available data on treatment of generalized myasthenia gravis, data on …
Unfortunately, there is limited data on the use of individual treatments in ocular myasthenia gravis and no data compar …
Treatment-refractory myasthenia gravis.
Silvestri NJ, Wolfe GI. Silvestri NJ, et al. J Clin Neuromuscul Dis. 2014 Jun;15(4):167-78. doi: 10.1097/CND.0000000000000034. J Clin Neuromuscul Dis. 2014. PMID: 24872217 Review.
Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. ...Thymectomy (in some cases repeat thymectomy) is another option in selected patients. Studies evaluating these and other forms of therapy …
Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. .. …
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Melzer N, et al. J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. J Neurol. 2016. PMID: 26886206 Free PMC article. Review.
Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission. ...Emphasizing evidence from clinical trials, we provide an updated overview on immunopathogenesis, and derived current and future treatment strategies …
Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission. ...Emphasizing evid …
Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.
Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, Shohaimi S, Mohammadi M. Salari N, et al. J Transl Med. 2021 Dec 20;19(1):516. doi: 10.1186/s12967-021-03185-7. J Transl Med. 2021. PMID: 34930325 Free PMC article.
There have been several preliminary studies on the epidemiology of myasthenia gravis in different parts of the world and the effectiveness of common drugs in its treatment, but there has been no comprehensive study of the efficacy of common drugs in the tr …
There have been several preliminary studies on the epidemiology of myasthenia gravis in different parts of the world and the e …
11,973 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "treatment myasthenia gravis"